Summer Sale! Save 25%
Free Express Shipping
Sale Ends: 06/27
Uses
Side effects
Interactions
Precautions
LATUDA is an atypical antipsychotic for the treatment of:
- Schizophrenia
- Depressive Episodes associated with Bipolar I Disorder (bipolar depression), as monotherapy and as adjunctive therapy with lithium or valproate
Commonly observed adverse reactions (incidence ≥ 5% and at least twice the rate for placebo) were:
- Schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea
- Bipolar depression: akathisia, extrapyramidal symptoms, and somnolence
- LATUDA is predominantly metabolized by CYP3A4. LATUDA should not be used concomitantly with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) or strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John’s wort, phenytoin, carbamazepine, etc.) [see Contraindications (4)]. The LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 (e.g., diltiazem, atazanavir, erythromycin, fluconazole, verapamil, etc.). If LATUDA is used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the LATUDA dose. Lithium: It is not necessary to adjust the LATUDA dose when used concomitantly with lithium. Valproate: It is not necessary to adjust the LATUDA dose when used concomitantly with valproate. A dedicated drug-drug interaction study has not been conducted with valproate and LATUDA. Based on pharmacokinetic data from the bipolar depression studies valproate levels were not affected by lurasidone, and lurasidone concentrations were not affected by valproate. Grapefruit: Grapefruit and grapefruit juice should be avoided in patients taking LATUDA
- No adjustment is needed on the dose of lithium, valproate, or substrates of P-gp or CYP3A4 when coadministered with LATUDA
- Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack)
- Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring..
- Tardive Dyskinesia: Discontinue if clinically appropriate.
- Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain.
– Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes.
